This work further confirms the upregulated metabolic expression of CYP3A4 decreases doxorubicin efficacy in confirmation with previous studies across multiple cancer types, including liver (58), colorectal (29), breast (59), and prostate (60). This evidence concerns the gene CYP3A4 and cancer.